Updated 170218
2.) The “Lyme Disease”
Patents – the
research fraud and racketeering complaint data for the DOJ to Prosecute.
Again, a little background about this Dearborn/OspA-scam, since it is the
central or essence of the crimes: “Dearborn” refers to the 1994 CDC
conference (took place in Dearborn, MI) where the testing for Lyme was
falsified, or changed from that which represented the Lyme spirochete as
just another relapsing fever organism,… to something else entirely contrived
(not even empirically perceived) and false. That event is discussed in this
video and the other ones in the YouTube series called “Lyme Crymes.”
For years, no one in the Cabal would admit that rOspA (recombinant outer
surface protein A of the Borrelia burgdorferi organism or the Lyme vaccines
that came and went) was Pam3Cys, because they couldn’t. If they said “OspA
is Pam3Cys,” everyone would know from officialdom that it was never a
vaccine and the ALDF.com’s (now IDSA’s) whole house of cards would
collapse. rOspA is a fungal antigen that causes immunosuppression – the
opposite of a “vaccine.” If OspA was not a vaccine, then the CDC’s 1994
“Dearborn” 2-tiered testing schema was a lie.
The falsified Dearborn case definition was the lie
invented to pass off bogus OspA vaccines. You can tell for sure because
they left OspA and B out (A and B are encoded on the same plasmid so you
can’t leave out one without the other) of the diagnostic standard. One
never tests for vaccine efficacy with the same antigen that is the vaccine.
For example, if someone made a recombinant measles vaccine based on a DNA
sequence that coded for say, “XYZ” surface antigen, they would not use
recombinant “XYZ” surface antigen in the testing schema to see if a person
had measles because they would not know if the antibody band was from the
organism or the vaccine.
It was known at least since the late 1980s that people with late neurologic
Lyme disease ceased to produce antibodies. However, the Dearborn case
definition (Steere, that is) rejected those classes of disease – early and
late meningitis or chronic neurologic cases - and said instead that only the
blatantly, highly immunoreactive class of Lyme victims, those with the
HLA-linked or arthritis-linked or hypersensitivity-linked cases, or those
who produced abundant IgG antibodies could be called a “case” of “Lyme
Disease.” This falsification of the testing was as much a semantics game
was it was straight up research fraud from these DNA patenteers. This
Dearborn event left the sickest people with no disease diagnosis.
If someone intended a monopoly on a new diseases set or
an entirely new class of diseases, such as what African vector borne
diseases arriving in North America were discovered to be, what would they
do? They’d make sure they got all of it: vaccines, test kits, grants,
funding, all future blood testing for all future potentially patentable
goodies in that blood, publicity, their names on plaques and statues (like
Alan Barbour), awards like an “Astute Clinician Award,”… or, they could be
knighted like Simon Wessely, a psychiatrist who helps by calling all the
victims of the Lyme scam and Gulf War Illness “crazy” and “terrorists,” or
like some US States naming, like, “Allen Steere Day” after them…
The Dearborn stunt is to the present day, the lie these criminals are trying
to defend by issuing fake “guidelines” based on the fraudulent, 2001,
Klempner non-retreatment report,
N Engl J Med. 2001
Jul 12;345(2):85-92.
Two controlled trials of antibiotic treatment in
patients with persistent symptoms and a history of Lyme disease.
Klempner MS1, Hu
LT, Evans
J, Schmid
CH, Johnson
GM, Trevino
RP, Norton
D, Levy
L, Wall
D, McCall
J, Kosinski
M, Weinstein
A.
http://www.ncbi.nlm.nih.gov/pubmed/11450676
and with this cabal’s chronic hystrionics over the development of other
tests for Lyme, etc., because that, Dearborn, will be the most serious
criminal charges – the Fraud, Negligence, and Denial of Rights via Color of
Law charges. All the ALDF.com and DNA patent-owners, here, have slandered
and libeled against Lyme victims, making this not a simply negligence
charge. All of their derogatory slander and label and trash-talking Lyme
and LYMErix victims show “intent to cause harm.”
Barbour, Alan G., CDC
officer and participant in the Dearborn conference, owns 30+ patents
including the ImmuLyme OspA patent. The ImmuLyme vaccine trial report
authors (Sigal, et al) and Barbour assert that one must be sure lipids are
attached to all Osps or else they will not be immunogenic, yet Steere’s
Dearborn panel was developed from high passage G39/40 and FRG with
recombinant OspA and B with no lipids attached, leaving OspA and B out of
the case definition panel.
Barbour’s ImmuLyme patent (&Berstrom, Magnarelli) European Patent #
(5092/88, DK)
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5523089.PN.&OS=PN/5523089&RS=PN/5523089
Yale’s LYMErix OspA patent (5,747,294):
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5747294.PN.&OS=PN/5747294&RS=PN/5747294
ImmuLyme trial result (falsified; used Dearborn, blots were unreadable):
N Engl J Med. 1998
Jul 23;339(4):216-22.
A vaccine consisting of recombinant Borrelia
burgdorferi outer-surface protein A to prevent Lyme
disease. Recombinant Outer-Surface
Protein A Lyme
Disease Vaccine Study
Consortium.
Sigal LH1, Zahradnik
JM, Lavin
P, Patella
SJ, Bryant
G, Haselby
R, Hilton
E, Kunkel
M, Adler-Klein
D, Doherty
T, Evans
J, Molloy
PJ, Seidner
AL, Sabetta
JR, Simon
HJ, Klempner
MS, Mays
J, Marks
D, Malawista
SE.
http://www.ncbi.nlm.nih.gov/pubmed/9673299
LYMErix trial result (falsified; used Dearborn, blots were unreadable):
N Engl J Med. 1998
Jul 23;339(4):209-15.
Vaccination against Lyme disease with recombinant
Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease
Vaccine Study Group.
Steere AC1, Sikand
VK, Meurice
F, Parenti
DL, Fikrig
E, Schoen
RT, Nowakowski
J, Schmid
CH, Laukamp
S, Buscarino
C, Krause
DS.
http://www.ncbi.nlm.nih.gov/pubmed/9673298
Barbour says OspA will not work as a vaccine due to antigenic variation,
1992:
J Exp Med. 1992
Sep 1;176(3):799-809.
Antibody-resistant mutants of Borrelia burgdorferi: in vitro selection and
characterization.
Sădziene A1, Rosa
PA, Thompson
PA, Hogan
DM, Barbour
AG.
http://www.ncbi.nlm.nih.gov/pubmed/1339462
Fikrig and Flavell say OspA will not work as a vaccine due to “selection
pressure” or antigenic variation, 1995:
Infect Immun. 1995
May;63(5):1658-62.
Selection of variant Borrelia burgdorferi
isolates from mice immunized with outer surface protein A or B.
Fikrig E1, Tao
H, Barthold
SW, Flavell
RA.
http://www.ncbi.nlm.nih.gov/pubmed/7729870
1992-1994. Steere Falsifies Test in Europe: uses “high passage strains” and
“OspA and B without the lipid attached” to leave OspA and B out of the
standard for his later monopoly on vector borne diseases testing. Only
Corixa, Imugen and Yale were to be licensed to use the RICO strain patent by
Dave Persing (US Patent # 6,045,804)
J Infect Dis. 1994
Feb;169(2):313-8.
Antibody responses to the three genomic groups of
Borrelia burgdorferi in European Lyme borreliosis.
Dressler F1, Ackermann
R, Steere
AC.
“The group 1 strain of
B. burgdorferi, G39/40, used in this study and in the previous study of US
patients was isolated from an Ixodes damini tick in Guilford, Connecticut
[21]. The group 2 strain, FRG [Federal Republic of Germany], was isolated
from Ixodes ricinus near Cologne [22]. The group 3 strain, IP3, was
isolated from Ixodes persulcatus near Leningrad [23]. All three strains
used in this study were high passage isolates, which were classified by
Richard Marconi (Rocky Mountain Laboratory, Hamilton, MT) using 16S
ribosomal RNA sequence determination as described [11, 24]. The recombinant
preparations of OspA and OspB used in this study were purified maltose-
binding protein-Osp fusion proteins derived from group 1 strain B31 [25].
The fusion proteins contained the full-length OspA or OspB sequence without
the lipid moiety or the signal sequence -"
http://www.ncbi.nlm.nih.gov/pubmed/8106763
Full Text @ http://www.actionlyme.org/STEERE_IN_EUROPE.htm
Dearborn: http://www.actionlyme.org/DEARBORN_PDF.pdf
See in the Dearborn booklet: none of the labs agreed with this Dearborn
proposal in that Dearborn pdf. (Except MarDx Labs, which was given
arthritis-positive blood to qualify their Western Blot strips prior to
Dearborn; MarDx was then was given both vaccine trial contracts; MarDx was
then sold to an company in Ireland, taking all the fraud data with them;
Trinity Biotech was the name of the company that bought MarDx).
The CDC sent labs an invitation to participate, but then CDC blew them all
off:
http://www.actionlyme.org/DEARBORNINVITATION.pdf
Barbour also patented Masters’ disease or STARI while
the crooks played the DNA/RNA shell game
to pull the wool over Edwin Masters’ eyes and to say “There is no ‘Lyme’ in
Missouri or the south.” To patent a unique species, you have to patent the
flagellin gene. The same should be true for diagnostics – using unique
recombinant flagellins from all Borreliae.
Telford Phylogeny with Masters’ Amblyomma Borrelia:
J Clin Microbiol. 2001
Feb;39(2):494-7.
Lone star tick-infecting borreliae are most
closely related to the agent of bovine borreliosis.
Rich SM1, Armstrong
PM, Smith
RD, Telford
SR 3rd.
http://www.ncbi.nlm.nih.gov/pubmed/11158095
Barbour’s Patent for Masters’ disease or something
close to it [either lonestari or barbouri; the phylogenetic data says they
are the same in 16S RNA and only slightly different in the flagellin gene
(96% homology), so both evolved from theileri, which is cow relapsing fever;
one species is now called barbouri and the other is called lonestari, but
really they are Masters disease, since he was the one who for years claimed
there was a Lyme-like illness in the south, associated with a Lyme-like rash
and tick bite]:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,932,220.PN.&OS=PN/5,932,220&RS=PN/5,932,220
Johnson, Barbara J., CDC
officer, Ft. Collins, CO., owner of 5 patents in Europe with SmithKline,
talks about differences in HLAs of mice, referring to their tendency to
produce HLA-linked hypersensitivity responses or not, meaning she is aware
that the same applies to humans.
CDC’s BJ Johnson oversaw this Dearborn-Falsification-of-Lyme-Testing stunt
(Oct 1994). She said to not use high passage strains, yet high passage
G39/40 and FRG (Federal Republic of Germany) were what Steere used to
develop the Dearborn panel along with recombinant OspA and B with no lipids
attached. This was done, again, to assure OspA and B were not included in
the Dearborn panel, … to facilitate what Steere, Corixa, L2 Diagnostics and
Imugen intended to do after LYMErix was on the market, … which was to
monopolize the Lyme or tick-borne diseases testing market where “the
vaccination status was unknown.” RICO patent 6.045,804]
Johnson’s Patents (5 in all):
http://worldwide.espacenet.com/publicationDetails/biblio?DB=worldwide.espacenet.com&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=19931209&CC=WO&NR=9324145A1&KC=A1
Dearborn Booklet http://www.actionlyme.org/DEARBORN_PDF.pdf
Fikrig and Flavell –
own both the only scientifically valid method to detect Lyme and also own
the LYMErix OspA patent. ***Their FDA-valid flagellin method was not used
to assess the outcome of LYMErix because they knew not only did LYMErix not
work because Lyme is a Relapsing Fever organism and undergoes antigenic
variation (OspA itself, Fikrig and Flavell said, undergoes antigenic
variation or “selection pressure” and would be no good as a vaccine), but
Pam3Cys or TLR2/1 agonists (OspA is Pam3Cys) are fungal and cause
immunosuppression in most people – especially people without Steere’s
alleged HLA-linked hypersensitivity responses.***
OspA patent
http://patft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5747294.PN.&OS=PN/5747294&RS=PN/5747294
Fikrig and Flavell’s (Yale’s) Valid (per FDA) flagellin method patent
5,618,533:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,618,533.PN.&OS=PN/5,618,533&RS=PN/5,618,533
The PubMed report that goes with the Yale FDA-validated flagellin method
(detects 94.4% of all cases, including earliest and late neurologic), 1991:
Infect Immun. 1991
Oct;59(10):3531-5.
Molecular characterization of the humoral
response to the 41-kilodalton flagellar antigen of Borrelia burgdorferi, the Lyme disease agent.
Berland R1, Fikrig
E, Rahn
D, Hardin
J, Flavell
RA.
http://www.ncbi.nlm.nih.gov/pubmed/1894359
Fikrig and Flavell say OspA will not work due to antigenic variation:
Infect Immun. 1995
May;63(5):1658-62.
Selection of variant Borrelia burgdorferi isolates
from mice immunized with outer surface protein A or B.
Fikrig E1, Tao
H, Barthold
SW, Flavell
RA.
http://www.ncbi.nlm.nih.gov/pubmed/7729870
Padula and OspC –
says Borrelia burgdorferi strain B31 has little to no OspC in it, meaning
whoever Western Blots with this strain will be leaving OspA, B and C out of
the standard. If you have those bands, you will be told you do not have
Lyme, yet they are the “primary, immunodominant antigens,” which was why
they got the assignments A, B, C, etc. SmithKline used this strain, B31, to
WB LYMErix victims and claimed to be using the Dearborn method to detect
Lyme or vaccine failure.
Padula OspC patent: USPatent No. 5,620,862
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5,620,862.PN.&OS=PN/5,620,862&RS=PN/5,620,862
Padula “OspC – not in strain B31” PubMed report:
Infect Immun. 1993
Dec;61(12):5097-105.
Molecular characterization and expression of p23
(OspC) from a North American strain of Borrelia burgdorferi.
Padula SJ1, Sampieri
A, Dias
F, Szczepanski
A, Ryan
RW.
http://www.ncbi.nlm.nih.gov/pubmed/8225587
Persing, Schoen and the RICO-within-the-RICO patent –
this patent shows the intention of Steere’s Dearborn, falsified case
definition (you will see later, in an announcement by the Mayo Clinic,
below).
US Patent # 6,045,804
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6,045,804.PN.&OS=PN/6,045,804&RS=PN/6,045,804
This patent reveals they know LYMErix causes a systemic
disease like chronic Lyme, and in this patent they reveal their intended
monopoly on post-LYMErix testing for the USA and Canada as they claimed in
their advertising:
"Additional uncertainty may arise if the vaccines are not completely
protective; vaccinated patients with multisystem
complaints characteristic of later presentations of Lyme disease may be
difficult to distinguish from patients with vaccine failure."
"The present invention provides a method useful to
detect a B. burgdorferi infection in a subject. The method provided by the
invention is particularly useful to discriminate B. burgdorferi infection
from OspA vaccination, although it is sufficiently sensitive and specific to
use in any general Lyme disease screening or diagnostic application. Thus,
the method of the invention is particularly appropriate for large scale
screening or diagnostic applications where only part of the subject
population has been vaccinated or where the vaccination status of the
population is unknown. "
Persing and Sigal later reveal that the Western Blots
in both vaccine trials were unreadable. Both vaccine trials used MarDx test
strips and said they were using the Dearborn method to assess the efficacies
of these vaccines. Arthur Weinstein was the Data Safety Monitor for one of
those trials and was also a participant in the Dearborn scam. Obviously
Weinstein never looked at any of the data he was safety-monitoring since the
Western Blots were unreadable. In reality, neither OspA vaccine trial group
could tell whether or not OspA prevented Lyme, so those vaccine trial
reports were research fraud events and reports.
This Persing-Schoen RICO-RICO Patent 6,045,804, is also written up this
PubMed report, co-written by Yale’s Robert Schoen:
J Clin Microbiol. 1997
Jan;35(1):233-8.
Borrelia burgdorferi enzyme-linked immunosorbent
assay for discrimination of OspA vaccination from spirochete infection.
Zhang YQ1, Mathiesen
D, Kolbert
CP, Anderson
J, Schoen
RT, Fikrig
E, Persing
DH.
http://www.ncbi.nlm.nih.gov/pubmed/8968914
Dattwyler, Raymond J. -
owns a patent that describes OspA as Pam3Cys. Therefore it could not have
been a blood-stream-injected “vaccine,” because it is a human TLR2/1
agonist. This Dattwyler patent is for an inhalation form of OspA/Pam3Cys.
Lung immunity is different from injecting fungal antigens directly into the
blood stream:
(US20090324638)
LIVE BACTERIAL VACCINE
"A lipidation/processing reaction has been described
for the intact OspA gene of B. burgdorferi. The primary translation product
of the full-length B. burgdorferi OspA gene contains a hydrophobic
N-terminal sequence, of 16 amino acids, which is a substrate for the
attachment of a diacyl glyceryl to the sulflhydryl side chain of the
adjacent cysteine (Cys) residue (at position 17). Following this attachment,
cleavage by signal peptidase II and the attachment of a third fatty acid to
the N-terminus occurs. The completed lipid moiety, a
tripalmitoyl-S-glycerylcysteine modification, is termed Pam3Cys (or is
sometimes referred to herein as Pam(3)Cys or Pam3Cys). It has been suggested
that the lipid modification allows membrane localization of proteins, with
polypeptide portions exposed as immune targets. In addition to serving as
targets for the immune response, Pam3Cys-modified proteins, such as OspA,
have been reported to act as potent inflammatory stimulants though the
toll-like 2 receptor mechanism (TLR2).
http://patentscope.wipo.int/search/en/detail.jsf?docId=US42934470&recNum=9&maxRec=30&office&prevFilter&sortOption=Pub+Date+Desc&queryString=tripalmitoyl+cysteine+or+Pam3Cys+and+Epstein-Barr&tab=NationalBiblio
==========
The Mayo Clinic advertised the RICO within the RICO – a
patent they were the assignee and would have gotten royalties (6,045,804);
CT AG and now Senator Richard Blumenthal’s staff were interested to know if
this RICO cabal including Yale, Imugen and Corixa ever advertised their
intended monopoly on post-LYMErix blood testing for North America “where the
vaccination status was unknown.” This is one example. Yale also advertised
this new test:
Can be found at:
https://groups.google.com/forum/#!original/sci.med.diseases.lyme/D6v-QHQdMbc/WupHjKwFilIJ
”http://www.mayo.edu/comm/mcr/news/news_361.html
“Mayo Clinic Rochester News
“ Tuesday, August 4, 1998
“New Tests Set Standard for Diagnosing Lyme Disease
ROCHESTER, MINN. — Mayo Medical Laboratories and IMUGEN
Inc. announced today the newest and most accurate test series available for
diagnosing Lyme disease. The tests also are the only reliable means of
diagnosing Lyme disease in people who have been vaccinated against Lyme
disease.
“Mayo Medical Laboratories, the laboratory for Mayo
Clinic, and IMUGEN Inc. of Norwood, Mass., are jointly offering the new
proprietary tests through local hospitals and clinics. Availability of the
new tests coincides with the anticipated release of new Lyme disease
vaccines, such as the widely-publicized LYMErix and ImuLyme.
”In research trials, all other Lyme tests have been shown to produce
false-positive results in people vaccinated against Lyme disease. Moreover,
the downstream costs of medical care delivered on the basis of just one
false-positive Lyme test can be as much as $15,000.
“According to Dr. David Persing, a Mayo Clinic
molecular biologist involved in the discovery of the new test components,
physicians now have a new and more reliable means of diagnosing patients who
present with symptoms of Lyme disease.
"These tests should help reduce the human and financial
costs associated with the number of undiagnosed, misdiagnosed, untreated or
improperly treated patients," Dr. Persing added.
”Scientists at IMUGEN, recognized nationally as the leading reference
laboratory for tick-borne diseases, are responsible for developing the
highly accurate immunologic methods to utilize Dr.Persing’s discovery.
"Diagnosing Lyme disease has been highly problematic
for a long time," said Victor Berardi, chief executive officer of IMUGEN,
whose laboratories have performed more than a half-million Lyme disease
tests. "Our new tests will greatly help physicians in distinguishing
patients who are actually infected from those who aren’. Furthermore, the
accuracy of these tests will not be affected by Lyme vaccine. In any case,
the tests will help physicians render more appropriate and cost effective
care."
“Lyme disease is a tick-borne illness that if left
undiagnosed or untreated can severely damage the human heart and nervous
system. Nationally more than 16,000 cases of Lyme disease were reported to
the Centers for Disease Control and Prevention (CDC) in 1996. The majority
of cases were reported in New England and the Northeast. The CDC reports
that the overall number of Lyme disease cases could climb to 25,710 by the
year 2000.
“In a study of 10,936 people in states with a high
incidence of Lyme disease, one new vaccine proved 79 percent effective at
preventing Lyme disease infections after complete dosage. Given the
potential popularity of the vaccine, and the recent epidemic of Lyme disease
in the Northeast, the new tests offered by Mayo Medical Laboratories and
IMUGEN will be of considerable value.
”The new Lyme disease tests detect multiple classes of antibody isotypes,
enabling them to discriminate between the vaccine and a true Lyme infection.
Existing Lyme disease tests, however, have shown to produce false-positive
results in patients vaccinated for Lyme disease.
“IMUGEN Inc. of Norwood, Mass., is a pioneer in the
research, development and testing of tick-borne diseases, including Lyme
disease, babesiosis and ehrlichiosis. For the past decade, IMUGEN has
provided clinics and hospitals in the Northeast with
high-quality serologic testing from its facilities in
Norwood, Mass., and Southhampton Hospital in Southhampton, N.Y. For more
information, call 781-255-0770.
“Mayo Medical Laboratories is the laboratory for Mayo
Clinic and provides lab services to community-based healthcare organizations
throughout the nation and world. Mayo Medical
Laboratories draws from the expertise of Mayo Clinic’s
1,600 physicians and scientists who provide specialized consultation on test
selection, utilization and interpretation.
“For information, call 800-533-1710.
###
“Contact: “Tom Huyck “507-284-0003 (days)
“507-284-2511 (evenings)”